Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

Summary

The purpose of this study is * to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), * to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, * to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).

Timeline

Start

2004-01

Primary completion

2006-01

Completion

2006-01

Drugs

Indications